<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Furosemide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Furosemide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Furosemide: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12503" href="/d/html/12503.html" rel="external">see "Furosemide: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13329" href="/d/html/13329.html" rel="external">see "Furosemide: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F7305944"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Fluid/electrolyte loss: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Furosemide is a potent diuretic that, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required and dose and dose schedule must be adjusted to the individual patient's needs.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F174841"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Furoscix;</li>
<li>Lasix</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867004"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Furosemide;</li>
<li>BIO-Furosemide [DSC];</li>
<li>Furosemide Special;</li>
<li>Lasix Oral;</li>
<li>Lasix Special;</li>
<li>MINT-Furosemide;</li>
<li>PMS-Furosemide [DSC];</li>
<li>PRO-Furosemide;</li>
<li>TEVA-Furosemide</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F174893"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antihypertensive;</li>
<li>
                        Diuretic, Loop</li></ul></div>
<div class="block doa drugH1Div" id="F174846"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Loop diuretic approximate oral dose equivalency for patients with normal kidney function: Furosemide 40 mg = bumetanide 1 mg = torsemide 10 to 20 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-6872415','lexi-content-ref-Brater.2019a','lexi-content-ref-21366472','lexi-content-ref-22676934','lexi-content-ref-7781259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-6872415','lexi-content-ref-Brater.2019a','lexi-content-ref-21366472','lexi-content-ref-22676934','lexi-content-ref-7781259'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b6fb7ac1-bbc8-410c-a521-e75c574154a6">Ascites due to cirrhosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ascites due to cirrhosis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Generally used in combination with spironolactone but may be used as monotherapy for patients with hyperkalemia. For combination therapy, a dosing ratio of spironolactone 100 mg to furosemide 40 mg should generally be maintained but can be adjusted for electrolyte abnormalities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23463403','lexi-content-ref-Runyon.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23463403','lexi-content-ref-Runyon.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 40 mg once daily; titrate every 3 to 5 days based on response and tolerability; once-daily dosing is preferred; maximum dose: 160 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23463403','lexi-content-ref-Runyon.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23463403','lexi-content-ref-Runyon.2020'])">Ref</a></span>). For small-volume ascites in patients who weigh &lt;50 kg, some experts recommend a starting dose of 20 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Runyon.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Runyon.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="64a84569-d387-4bc2-8369-8004ca9fc0a4">Edema or volume overload</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Edema or volume overload:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Naive to loop diuretics:</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral, IV:</b> Initial: 20 to 40 mg once then titrate as needed to an effective dose (see "Titration to effect" below) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-22099505','lexi-content-ref-Sterns.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-22099505','lexi-content-ref-Sterns.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Oral bioavailability varies widely but on average is 50% of the IV dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22099505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22099505'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Refractory edema or acute decompensation in patients taking oral loop diuretics: </i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Bolus/intermittent dosing:</b>
<b>IV: </b>Initial: Administer 1 to 2.5 times the total daily oral maintenance dose once (eg, a patient taking oral furosemide 40 mg twice daily at home [80 mg/day] can be given 80 mg to 200 mg IV as an initial bolus) then titrate as needed to an effective dose; maximum effective single dose: 80 to 200 mg depending on kidney function (see "Titration to effect" below) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31526538','lexi-content-ref-22099505','lexi-content-ref-Brater.2020','lexi-content-ref-Brater.2019a','lexi-content-ref-Colucci.2019','lexi-content-ref-21366472']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31526538','lexi-content-ref-22099505','lexi-content-ref-Brater.2020','lexi-content-ref-Brater.2019a','lexi-content-ref-Colucci.2019','lexi-content-ref-21366472'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>
<i>Titration to effect:</i></b> If the initial dose does not result in diuresis, double the individual dose (rather than administer the same dose more frequently) until diuresis occurs. Titration of an IV dose can occur at ≥2-hour intervals as needed in hospitalized patients. Once an effective dose is identified, it is typically administered once or twice daily but may be given more frequently if needed. The maximum effective dose varies by population; higher-than-usual doses may be required for patients with nephrotic syndrome or kidney failure; maximum effective single dose: 80 to 200 mg; maximum recommended total daily dose: 600 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31526538','lexi-content-ref-35363499','lexi-content-ref-22099505','lexi-content-ref-Brater.2019a','lexi-content-ref-Brater.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31526538','lexi-content-ref-35363499','lexi-content-ref-22099505','lexi-content-ref-Brater.2019a','lexi-content-ref-Brater.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Continuous infusion:</b>
<b>IV: </b>
<b>Note:</b> Reserve for patients who have responded to bolus therapy but need ongoing and sustained diuresis; administer continuous infusion immediately after effective bolus dose.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV:</b> Initial: 5 mg/hour; if diuretic response is not adequate, repeat IV bolus dose and increase continuous infusion to 10 mg/hour; continue to bolus and titrate infusion as needed up to 40 mg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22099505','lexi-content-ref-Brater.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22099505','lexi-content-ref-Brater.2020'])">Ref</a></span>). <b>Note:</b> In patients with eGFR &lt;30 mL/minute/1.73m<sup>2</sup>, higher doses may be necessary (see “Dosing: Altered Kidney Function: Adult”).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> Higher continuous infusion rates have been described but are not recommended due to potential for side effects; consider alternative strategies for fluid removal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Brater.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Brater.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ (Furoscix): </b>Preprogrammed on-body infusor delivers 30 mg over the first hour, followed by 12.5 mg per hour for the next 4 hours; total dose: 80 mg over 5 hours. <b>Note:</b> Not for chronic use; switch to oral diuretics as soon as clinically practical.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Transitioning from IV or SUBQ to oral:</b></i> There is substantial variability in oral bioavailability; typically administer 1 to 2 times the IV or SUBQ dose orally (eg, total daily IV or SUBQ dose of 80 mg/day should be converted to an oral dose of 80 to 160 mg/day in 1 to 2 divided doses); monitor urine output and adjust oral dose as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22099505','lexi-content-ref-Brater.2020','lexi-content-ref-7120755','lexi-content-ref-9017769','lexi-content-ref-7781259','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22099505','lexi-content-ref-Brater.2020','lexi-content-ref-7120755','lexi-content-ref-9017769','lexi-content-ref-7781259','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990435"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> There are no dosage adjustments provided in the manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: IV, Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV, Oral: </b>Higher doses may be required to achieve desired diuretic response due to decreased secretion into the tubular fluid. However, single doses &gt;160 to 200 mg IV (or oral equivalent) are unlikely to result in additional diuretic effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22099505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22099505'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Continuous infusion: </i>IV: </b>Initial: 20 mg/hour; if diuretic response is not adequate, repeat IV bolus dose and increase continuous infusion to 40 mg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22099505','lexi-content-ref-Brater.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22099505','lexi-content-ref-Brater.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4842808','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4842808','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Anuric patients:</i> There is no expected clinical benefit; use not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18048421']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18048421'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients with residual kidney function:</i> Dose as per eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8641327']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8641327'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Anuric patients:</i> There is no expected clinical benefit; use not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18048421']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18048421'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients with residual kidney function:</i> Dose as per eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>. <b>Note:</b> If necessary, limited (single dose) data suggest that an oral dose of 500 mg may be more effective than 250 mg in increasing urine output (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31657712']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31657712'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b> In general, use not recommended; fluid management can be more effectively managed using CRRT ultrafiltration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Close monitoring of response and adverse reactions (eg, ototoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Anuric patients:</i> There is no expected clinical benefit; use not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients with residual kidney function:</i> Dose as per eGFR &lt;30 mL/minute/1.73 m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987620"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV, Oral: </b>Diminished natriuretic effect with increased sensitivity to hypokalemia and volume depletion in cirrhosis. Monitor effects, particularly with high doses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F174847"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral, IV:</b> Initial: 20 mg/day; increase slowly to desired response.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F174871"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13329" href="/d/html/13329.html" rel="external">see "Furosemide: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Oral and parenteral (IV, IM) doses may not be interchangeable; due to differences in bioavailability, oral doses are typically higher than IV. Oral solution is available in multiple concentrations (8 mg/mL and 10 mg/mL); extra precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as mg (not mL). Dose equivalency for adult patients with normal renal function (approximate): Furosemide 40 mg = bumetanide 1 mg = torsemide 10 to 20 mg. <b>Note:</b> Ethacrynic acid has a relative potency of 0.7 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6872415','lexi-content-ref-8074594','lexi-content-ref-22676934','lexi-content-ref-Jackson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6872415','lexi-content-ref-8074594','lexi-content-ref-22676934','lexi-content-ref-Jackson.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6b3bf4fb-d61c-4d60-acaa-a34bb1a9f68a">Edema</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Edema (diuresis):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent dosing (acute): Oral: Initial: 2 mg/kg as a single dose; if ineffective, may increase in 6 to 8 hours in increments of 1 to 2 mg/kg/dose; maximum dose: 6 mg/kg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance dosing (chronic): Limited data available: Oral: Initial: 0.5 to 2 mg/kg/dose every 6 to 24 hours; usual initial adult dose: 20 to 40 mg/dose; if initial dose ineffective, may increase dose in increments of 1 to 2 mg/kg/dose; maximum daily dose: 6 mg/kg/<b>day</b>, not to exceed maximum adult daily dose: 600 mg/<b>day</b>; adjust dose to minimal effective dose for maintenance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-21242810','lexi-content-ref-32232733','lexi-content-ref-15286277','lexi-content-ref-Rosanno.1','lexi-content-ref-16898855','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-21242810','lexi-content-ref-32232733','lexi-content-ref-15286277','lexi-content-ref-Rosanno.1','lexi-content-ref-16898855','lexi-content-ref-manu.1'])">Ref</a></span>). <b>Note:</b> Smaller doses on a mg/kg basis may be needed in larger children, especially in those who are diuretic naive.</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent IV, IM: Infants, Children, and Adolescents: Limited data available: Initial: 0.5 to 2 mg/kg/dose every 6 to 12 hours; usual initial adult dose: 20 to 40 mg/dose; if initial dose ineffective after 2 hours, may increase dose by 1 mg/kg/dose; maximum dose: 6 mg/kg/dose, not to exceed maximum adult dose: 200 mg/dose; adjust to minimal effective dose for maintenance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22099505','lexi-content-ref-Erkan.1','lexi-content-ref-Fuhrman.2017','lexi-content-ref-Rosanno.1','lexi-content-ref-16898855','lexi-content-ref-2184406']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22099505','lexi-content-ref-Erkan.1','lexi-content-ref-Fuhrman.2017','lexi-content-ref-Rosanno.1','lexi-content-ref-16898855','lexi-content-ref-2184406'])">Ref</a></span>). <b>Note:</b> Smaller doses on a mg/kg basis may be needed in larger children, especially in those who are diuretic naive. Dosing in adolescents based on experience in adult and pediatric patients.</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: Limited data available: Initial: IV bolus dose of 1 to 2 mg/kg (reported range, 0.1 to 2 mg/kg) followed by continuous IV infusion of 0.05 to 0.4 mg/kg/<b>hour</b>; titrate dosage to clinical effect; doses up to 1 mg/kg/hour have been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33796993','lexi-content-ref-6650766','lexi-content-ref-19142668','lexi-content-ref-9354540','lexi-content-ref-32232733','lexi-content-ref-24897942','lexi-content-ref-1729038','lexi-content-ref-11398698']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33796993','lexi-content-ref-6650766','lexi-content-ref-19142668','lexi-content-ref-9354540','lexi-content-ref-32232733','lexi-content-ref-24897942','lexi-content-ref-1729038','lexi-content-ref-11398698'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Very limited data available; dosing in adolescents based on reported experience in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22099505','lexi-content-ref-19142668','lexi-content-ref-9354540','lexi-content-ref-24897942','lexi-content-ref-1729038','lexi-content-ref-11398698']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22099505','lexi-content-ref-19142668','lexi-content-ref-9354540','lexi-content-ref-24897942','lexi-content-ref-1729038','lexi-content-ref-11398698'])">Ref</a></span>): IV bolus dose of 0.1 to 2 mg/kg; usual adult bolus dose: 40 mg over 1 to 2 minutes, followed by continuous IV infusion of 0.1 to 0.4 mg/kg/<b>hour</b>; usual adult dosing range: 10 to 40 mg/<b>hour</b>.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51130589"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">IV, Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">There are no pediatric-specific recommendations; in adults with acute renal failure, very high doses may be necessary to initiate diuretic effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22099505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22099505'])">Ref</a></span>); avoid use in oliguric states.</p>
<p style="text-indent:-2em;margin-left:2em;">Dialysis: Not removed by hemo- or peritoneal dialysis; supplemental dose is not necessary.</p></div>
<div class="block dohp drugH1Div" id="F51110602"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">IV, Oral: Diminished natriuretic effect with increased sensitivity to hypokalemia and volume depletion in cirrhosis; monitor effects, particularly with high doses.</p></div>
<div class="block arsc drugH1Div" id="F54992848"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Acute kidney injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Loop diuretics, including furosemide, may lead to <b>acute kidney injury</b> due to fluid loss (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33824870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33824870'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; related to the pharmacologic action (ie, volume depletion) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22099511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22099511'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Excessive doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10653441','lexi-content-ref-24940940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10653441','lexi-content-ref-24940940'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent administration of nephrotoxic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10653441','lexi-content-ref-24940940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10653441','lexi-content-ref-24940940'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10653441','lexi-content-ref-24940940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10653441','lexi-content-ref-24940940'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting volume depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10653441','lexi-content-ref-24940940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10653441','lexi-content-ref-24940940'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Reduced blood flow to the kidney or depletion of effective blood volume (eg, bilateral renal artery stenosis, cirrhosis, nephrotic syndrome, heart failure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24940940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24940940'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Critically ill (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22641414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22641414'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Fluid/electrolyte loss</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Loop diuretics, including furosemide, may lead to profound diuresis (especially if given in excessive amounts), resulting in <b>hypovolemia </b>and electrolyte loss. Electrolyte disturbances (eg, <b>hypocalcemia</b>, <b>hypokalemia, hypomagnesemia</b>) may predispose a patient to serious cardiac arrhythmias.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; related to the pharmacologic action (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10653441','lexi-content-ref-20085566','lexi-content-ref-26951244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10653441','lexi-content-ref-20085566','lexi-content-ref-26951244'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Excessive doses with initiation or dose adjustment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10653441','lexi-content-ref-26240596']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10653441','lexi-content-ref-26240596'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Reduced dietary fluid and/or electrolyte intake (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10653441','lexi-content-ref-26240596']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10653441','lexi-content-ref-26240596'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent illness leading to excessive fluid loss (eg, diarrhea, vomiting) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10653441','lexi-content-ref-21896142']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10653441','lexi-content-ref-21896142'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant administration of an additional diuretic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10653441','lexi-content-ref-21896142']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10653441','lexi-content-ref-21896142'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Very high or very restricted dietary sodium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10653441','lexi-content-ref-22099511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10653441','lexi-content-ref-22099511'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immediate hypersensitivity reactions, including <b>angioedema</b>, <b>urticaria,</b> and <b>anaphylaxis</b> have been reported with furosemide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20084851','lexi-content-ref-14670291','lexi-content-ref-3668117']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20084851','lexi-content-ref-14670291','lexi-content-ref-3668117'])">Ref</a></span>). Delayed hypersensitivity reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29409745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29409745'])">Ref</a></span>) range from maculopapular <b>skin rash</b> to rare severe cutaneous adverse reactions (SCARs), including <b>acute generalized exanthematous pustulosis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11093686']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11093686'])">Ref</a></span>), <b>drug reaction with eosinophilia and systemic symptoms</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29440628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29440628'])">Ref</a></span>), <b>Stevens-Johnson syndrome</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21507837']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21507837'])">Ref</a></span>) and <b>toxic epidermal necrolysis</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non-dose-related; immunologic. Immediate hypersensitivity reactions: IgE-mediated, with specific antibodies formed against a drug allergen following initial exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-14670291','lexi-content-ref-3668117']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-14670291','lexi-content-ref-3668117'])">Ref</a></span>). SCARs: Delayed type IV hypersensitivity reactions involving a T-cell mediated drug-specific immune response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Immediate hypersensitivity reactions: Rapid; generally occurs within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-14670291','lexi-content-ref-3668117','lexi-content-ref-NICE.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-14670291','lexi-content-ref-3668117','lexi-content-ref-NICE.2014'])">Ref</a></span>). Delayed hypersensitivity reactions: Varied; typically occur days to 12 weeks after drug exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29440628','lexi-content-ref-21507837']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29440628','lexi-content-ref-21507837'])">Ref</a></span>) but may occur more rapidly (usually within 1 to 4 days) upon reexposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-NICE.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-NICE.2014'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity: Cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides (such as furosemide) may not occur, or at the very least this potential is extremely low (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15303450','lexi-content-ref-31495421','lexi-content-ref-15242722','lexi-content-ref-23943179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15303450','lexi-content-ref-31495421','lexi-content-ref-15242722','lexi-content-ref-23943179'])">Ref</a></span>). Cross-reactivity due to antibody production (anaphylaxis) is unlikely to occur with antibiotic sulfonamides and nonantibiotic sulfonamides (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31495421']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31495421'])">Ref</a></span>). There is limited published information regarding cross-reactivity between furosemide and other sulfonamides (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14670291','lexi-content-ref-3668117','lexi-content-ref-16105640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14670291','lexi-content-ref-3668117','lexi-content-ref-16105640'])">Ref</a></span>) and among other sulfonamide loop diuretics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16352777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16352777'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ototoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Loop diuretics, including furosemide, have been associated with hearing loss (<b>deafness</b>) and <b>tinnitus,</b> which is generally reversible (lasting from 30 minutes to 24 hours after administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29937824','lexi-content-ref-496112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29937824','lexi-content-ref-496112'])">Ref</a></span>)). Cases of permanent hearing loss have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9165341','lexi-content-ref-8233492']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9165341','lexi-content-ref-8233492'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; related to the pharmacologic action (ie, inhibition of a secretory isoform of the Na-K-2Cl co-transporter in the inner ear and impacts on ionic composition of cochlear fluids) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10369265','lexi-content-ref-496112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10369265','lexi-content-ref-496112'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-496112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-496112'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Excessive doses</p>
<p style="text-indent:-2em;margin-left:6em;">• IV administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-496112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-496112'])">Ref</a></span>); bolus (higher risk) versus continuous infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8800113']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8800113'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other ototoxic agents (eg, aminoglycosides) can lead to ototoxicity at lower doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7042998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7042998'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Premature very low birth weight (VLBW) neonates due to immature kidney function (ie, PMA &lt;31 weeks with doses given more frequently than every 24 hours; PMA ≥31 weeks with dose given more frequently than every 12 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3351693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3351693'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F174805"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Necrotizing angiitis (Hendricks 1977), orthostatic hypotension, thrombophlebitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Noce 2000), bulla (hemorrhagic) (Sladden 2016), bullous pemphigoid (Lee 2006), erythema multiforme (Zugerman 1980), exfoliative dermatitis, lichenoid eruption (Arias-Santiago 2010), pruritus, skin photosensitivity (Moore 2002), skin rash, Stevens-Johnson syndrome (Wright 2010), toxic epidermal necrolysis, urticaria (Dominguez-Ortega 2003)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Glycosuria, hyperglycemia, hyperuricemia, hypocalcemia, hypochloremic alkalosis, hypokalemia, hypomagnesemia, hypovolemia, increased serum cholesterol, increased serum triglycerides</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps, anorexia, constipation, diarrhea, gastric irritation, nausea, oral irritation, pancreatitis, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Bladder spasm</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, anemia, aplastic anemia, hemolytic anemia (Maddox 1992), leukopenia (Ma 2017), purpuric disease, thrombocytopenia (Ochoa 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic encephalopathy, increased liver enzymes, intrahepatic cholestatic jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis (Dominguez-Ortega 2003), angioedema (Dominguez-Ortega 2003), nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (James 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, headache, paresthesia, restlessness, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia, muscle spasm</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, xanthopsia</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Deafness (Rifkin 1978), tinnitus (Skeith 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury, calcium nephrolithiasis (pediatric patients), interstitial nephritis (allergic) (Jennings 1986), nephrolithiasis (pediatric patients)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (Edrup 2010)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Exacerbation of diabetes mellitus, hyponatremia (in combination with spironolactone in patients with heart failure) (Velat 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Tetany</p></div>
<div class="block coi drugH1Div" id="F174820"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to furosemide or any component of the formulation; anuria; ascites or hepatic cirrhosis (Furoscix).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to sulfonamide-derived drugs; complete kidney shutdown; hepatic coma and precoma; uncorrected states of electrolyte depletion, hypovolemia, dehydration, or hypotension; jaundiced newborn infants or infants with disease(s) capable of causing hyperbilirubinemia and possibly kernicterus; breastfeeding. <b>Note:</b> Manufacturer labeling for Lasix Special and Furosemide Special Injection also includes: GFR &lt;5 mL/minute or GFR &gt;20 mL/minute; hepatic cirrhosis; kidney failure accompanied by hepatic coma and precoma; kidney failure due to poisoning with nephrotoxic or hepatotoxic substances; pediatric patients ≤15 years of age.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Although the FDA-approved product labeling states this medication is contraindicated in patients with hypersensitivity to sulfonamide-containing drugs, the scientific basis of this cross-sensitivity has been challenged. See "Warnings/Precautions" for more detail.</p></div>
<div class="block war drugH1Div" id="F174802"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperuricemia: Asymptomatic hyperuricemia has been reported with use; rarely, may precipitate gout.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfonamide (“sulfa”) allergy: The approved product labeling for many medications containing a sulfonamide chemical group includes a broad contraindication in patients with a prior allergic reaction to sulfonamides. There is a potential for cross-reactivity between members of a specific class (eg, two antibiotic sulfonamides). However, concerns for cross-reactivity have previously extended to all compounds containing the sulfonamide structure (SO<sub>2</sub>NH<sub>2</sub>). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides. T-cell-mediated (type IV) reactions (eg, maculopapular rash) are not well understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/toxic epidermal necrolysis), some clinicians choose to avoid exposure to these classes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid effects: Doses &gt;80 mg may result in transient increase in free thyroid hormones, followed by an overall decrease in total thyroid hormone levels.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal insufficiency: Avoid use of diuretics for treatment of elevated blood pressure in patients with primary adrenal insufficiency (Addison disease). Adjustment of glucocorticoid/mineralocorticoid therapy and/or use of other antihypertensive agents is preferred to treat hypertension (Bornstein 2016; Inder 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery: Dehydration: Avoid diuretics in the immediate postoperative period after bariatric surgery; electrolyte disturbances and dehydration may occur. Diuretics may be resumed, if indicated, once oral fluid intake goals are met (Ziegler 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cirrhosis: In cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy; correct electrolyte and acid/base imbalances prior to initiation when hepatic coma is present. Supplemental potassium or an aldosterone antagonist, when appropriate, may reduce risk of hypokalemia and metabolic alkalosis. Close monitoring warranted, especially with initiation of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostatic hyperplasia/urinary stricture: May cause urinary retention due to increased urine production, especially upon initiation of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic lupus erythematosus: May cause systemic lupus erythematosus exacerbation or activation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: May lead to nephrocalcinosis or nephrolithiasis in premature infants and in infants and children &lt;4 years of age with chronic use. May prevent closure of patent ductus arteriosus in premature infants.</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical patients: If given the morning of surgery, furosemide may render the patient volume depleted and blood pressure may be labile during general anesthesia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• On-body infusor (Furoscix): Not for chronic use; switch to oral diuretics as soon as clinically practical. Do not use in an MRI setting.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings and precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diuretic resistance: For some patients, despite high doses of loop diuretic, an adequate diuretic response cannot be attained. Diuretic resistance may be overcome by IV rather than oral administration or the use of two diuretics together (eg, a loop diuretic in combination with a thiazide diuretic). When multiple diuretics are used, serum electrolytes need to be monitored even more closely (ACC [Hollenberg 2019]).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878470"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Furosemide stimulates prostaglandin E2 (PGE2) which may prevent closure of patent ductus arteriosus (PDA) in premature infants. However, one large, retrospective cohort study involving 43,576 VLBW infants (median birth weight and GA: 1,120 g and 29 weeks) evaluated the association between the exposure to furosemide and the occurrence of PDA. Exposure to furosemide was not associated with an increased odds of PDA treatment (Thompson 2018). Another smaller placebo-controlled study (n=68, GA: &lt;34 weeks, birth weight: &lt;2,000 g) found no difference in PDA closure rate between patients treated with furosemide or placebo in combination with indomethacin (Lee 2010).</p></div>
<div class="block foc drugH1Div" id="F174813"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cartridge Kit, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Furoscix: 80 mg/10 mL (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (2 mL, 4 mL, 10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (2 mL, 4 mL, 10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 8 mg/mL (500 mL); 10 mg/mL (60 mL, 120 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lasix: 20 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lasix: 40 mg, 80 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg, 40 mg, 80 mg</p></div>
<div class="block geq drugH1Div" id="F174798"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F174822"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cartridge Kit</b> (Furoscix Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg/10 mL (per each): $1,077.65</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Furosemide Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $0.30 - $1.06</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Furosemide Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mg/mL (per mL): $0.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $0.15 - $0.17</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Furosemide Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.09 - $0.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $0.09 - $0.59</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $0.44 - $1.57</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Lasix Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.94</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $1.32</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $2.13</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867005"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (2 mL, 4 mL, 25 mL, 30 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (25 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lasix Oral: 10 mg/mL (120 mL) [contains alcohol, usp, methylparaben, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lasix Special: 500 mg [contains fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg, 40 mg, 80 mg</p></div>
<div class="block adm drugH1Div" id="F174817"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> May administer with or without food.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral:</b> Undiluted direct IV injections may be administered at a rate of 20 to 40 mg per minute; for high doses (eg, ≥160 mg), consider a short-term infusion at a maximum rate of administration of 4 mg/minute; rapid administration increases the risk of ototoxicity due to the high concentrations achieved in a short period of time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Brater.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Brater.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> On-body infusor (Furoscix): Administer in a setting where the patient can limit activity (limit bending; do not wear while riding in a car or flying) for the duration of administration and has access to a bathroom; not for use in an MRI setting. Prior to use, load the prefilled cartridge into the on-body infusor; do not use any other cartridges or medicines inside the on-body infusor. Select a clean, dry, hairless or nearly hairless area of the abdomen between the top of the beltline and the bottom of the ribcage (distance between top of beltline and bottom of ribcage should be at least 2½ inches); do not apply lotions, oils, or ointments to the area infusor will be applied; wipe the area where on-body infusor will be applied with an alcohol wipe and allow to dry; rotate sites with each administration and do not apply to bruised, indurated, red, or tender areas. Remove the adhesive liner and apply on-body infusor so the cartridge window and indicator light can be seen. Firmly press the start button to begin administration; a solid green status light, beeping sound, and a white plunger rod will fill the cartridge window when administration is complete (do not remove injection until complete). Keep on-body infusor dry; do not shower, swim, or do activities that cause sweating while wearing the on-body infusor. Do not use on-body infusor within 12 inches of mobile phones, tablets, computers, or wireless accessories (eg, TV remote control, Bluetooth computer keyboard, or Bluetooth mouse). For single use only; dispose of the on-body infusor in a sharps container after use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> When IV or oral administration is not possible, the sublingual route may be used. Place 1 tablet under tongue for at least 5 minutes to allow for maximal absorption. Patients should be advised not to swallow during disintegration time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17875188']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17875188'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52612896"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May administer with food or milk to decrease GI distress.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Administer undiluted; in general, reserve use for when enteral or IV administration is not clinically appropriate or feasible (eg, no IV access) and timely administration of furosemide is warranted (eg, acute pulmonary edema).</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent IV: May be administered undiluted direct IV at a usual rate of 0.5 to 1 mg/kg/minute (not to exceed 4 mg/minute); in adults, 20 to 40 mg undiluted solution may be administered over 1 to 2 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Administer diluted or undiluted as a continuous IV infusion with the use of an infusion pump.</p></div>
<div class="block uica drugH1Div" id="F14472639"><span class="drugH1">Usual Infusion Concentrations: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV infusion:</b> 1 mg/mL <b>or</b> 2 mg/mL <b>or</b> undiluted as 10 mg/mL</p></div>
<div class="block uicp drugH1Div" id="F14472640"><span class="drugH1">Usual Infusion Concentrations: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>IV infusion:</b> 1 mg/mL <b>or</b> 2 mg/mL <b>or</b> undiluted as 10 mg/mL</p></div>
<div class="block use drugH1Div" id="F174816"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Edema or volume overload:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Lasix and generics:</b> Management of edema associated with heart failure, cirrhosis of the liver (ie, ascites), or kidney disease (including nephrotic syndrome); acute pulmonary edema.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Furoscix:</b> Treatment of congestion due to fluid overload in adult patients with New York Heart Association class II and class III chronic heart failure.</p>
<p style="text-indent:-2em;margin-left:6em;">Limitations of use: Not indicated for use in emergency situations or patients with acute pulmonary edema.</p></div>
<div class="block mst drugH1Div" id="F174902"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Furosemide may be confused with famotidine, finasteride, fluconazole, FLUoxetine, fosinopril, loperamide, torsemide</p>
<p style="text-indent:-2em;margin-left:4em;">Lasix may be confused with Lanoxin, Lidex, Lomotil, Lovenox, Luvox, Luxiq, Wakix</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Diuretics are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Lasix [US, Canada, and multiple international markets] may be confused with Esidrex brand name for hydrochlorothiazide [multiple international markets]; Esidrix brand name for hydrochlorothiazide [Germany]; Losec brand name for omeprazole [multiple international markets]</p>
<p style="text-indent:-2em;margin-left:4em;">Urex [Australia, Hong Kong, Turkey] may be confused with Eurax brand name for crotamiton [US, Canada, and multiple international markets]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299370"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3; <b>Inhibits</b> MRP2</p></div>
<div class="block dri drugH1Div" id="F174807"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acebrophylline: May enhance the therapeutic effect of Furosemide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: May decrease the serum concentration of Furosemide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Allopurinol: Loop Diuretics may enhance the adverse/toxic effect of Allopurinol. Loop Diuretics may increase the serum concentration of Allopurinol. Specifically, Loop Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amikacin Liposome (Oral Inhalation): Loop Diuretics may enhance the nephrotoxic effect of Amikacin Liposome (Oral Inhalation). Loop Diuretics may enhance the ototoxic effect of Amikacin Liposome (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: Loop Diuretics may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Loop Diuretics may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Loop Diuretics may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Loop Diuretics may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihypertensive Agents: Loop Diuretics may enhance the hypotensive effect of Antihypertensive Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arsenic Trioxide: Loop Diuretics may enhance the hypotensive effect of Arsenic Trioxide. Loop Diuretics may enhance the QTc-prolonging effect of Arsenic Trioxide.  Management: When possible, avoid concurrent use of arsenic trioxide with drugs that can cause electrolyte abnormalities, such as the loop diuretics.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta2-Agonists: May enhance the hypokalemic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bilastine: Loop Diuretics may enhance the QTc-prolonging effect of Bilastine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Canagliflozin: May enhance the hypotensive effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Loop Diuretics may enhance the adverse/toxic effect of Cardiac Glycosides. Specifically, cardiac glycoside toxicity may be enhanced by the hypokalemic and hypomagnesemic effect of loop diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefaloridine [Cephaloridine]: Loop Diuretics may enhance the nephrotoxic effect of Cefaloridine [Cephaloridine]. Loop Diuretics may increase the serum concentration of Cefaloridine [Cephaloridine]. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefazedone: May enhance the nephrotoxic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefotiam: Loop Diuretics may enhance the nephrotoxic effect of Cefotiam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefpirome: Loop Diuretics may enhance the nephrotoxic effect of Cefpirome. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceftizoxime: Loop Diuretics may enhance the nephrotoxic effect of Ceftizoxime. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalosporins: Furosemide may enhance the nephrotoxic effect of Cephalosporins. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalothin: Loop Diuretics may enhance the nephrotoxic effect of Cephalothin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephradine: May enhance the nephrotoxic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: Furosemide may enhance the adverse/toxic effect of Chloral Betaine.  Management: Consider alternatives to this combination when possible; if combined use cannot be avoided, monitor closely for evidence of toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Hydrate: Furosemide may enhance the adverse/toxic effect of Chloral Hydrate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CISplatin: Loop Diuretics may enhance the nephrotoxic effect of CISplatin. Loop Diuretics may enhance the ototoxic effect of CISplatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the hypokalemic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): May enhance the adverse/toxic effect of Loop Diuretics. Specifically, the risk for hyperuricemia and gout may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: May enhance the hyponatremic effect of Loop Diuretics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diacerein: May enhance the therapeutic effect of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: Loop Diuretics may enhance the hypokalemic effect of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: Loop Diuretics may enhance the QTc-prolonging effect of Dofetilide.  Management: Monitor serum potassium and magnesium more closely when dofetilide is combined with loop diuretics. Electrolyte replacements will likely be required to maintain potassium and magnesium serum concentrations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Empagliflozin: May enhance the hypotensive effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ethacrynic Acid: Furosemide may enhance the ototoxic effect of Ethacrynic Acid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant). Management: Avoid use of fexinidazole with OAT1/3 substrates when possible. If combined, monitor for increased OAT1/3 substrate toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Foscarnet: Loop Diuretics may increase the serum concentration of Foscarnet.  Management: When diuretics are indicated during foscarnet treatment, thiazides are recommended over loop diuretics. If patients receive loop diuretics during foscarnet treatment, monitor closely for evidence of foscarnet toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: May diminish the diuretic effect of Furosemide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iodinated Contrast Agents: Loop Diuretics may enhance the nephrotoxic effect of Iodinated Contrast Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipragliflozin: May enhance the adverse/toxic effect of Loop Diuretics. Specifically, the risk for intravascular volume depletion may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Loop Diuretics may enhance the arrhythmogenic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Loop Diuretics may enhance the adverse/toxic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Licorice: May enhance the hypokalemic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Loop Diuretics may decrease the serum concentration of Lithium. Loop Diuretics may increase the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Sulfonamides may enhance the adverse/toxic effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May diminish the therapeutic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Methotrexate. Methotrexate may increase the serum concentration of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Netilmicin (Ophthalmic): Loop Diuretics may enhance the nephrotoxic effect of Netilmicin (Ophthalmic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Loop Diuretics may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitisinone: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May diminish the diuretic effect of Loop Diuretics. Loop Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Management: Monitor for evidence of kidney injury or decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concurrent use in CHF or cirrhosis. Concomitant use of bumetanide with indomethacin is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May diminish the therapeutic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Norepinephrine: Furosemide may diminish the therapeutic effect of Norepinephrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: May enhance the adverse/toxic effect of Diuretics. Opioid Agonists may diminish the therapeutic effect of Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Diuretics may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May diminish the diuretic effect of Loop Diuretics. Probenecid may increase the serum concentration of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: Loop Diuretics may enhance the QTc-prolonging effect of Promazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reboxetine: May enhance the hypokalemic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: Loop Diuretics may enhance the adverse/toxic effect of RisperiDONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May diminish the therapeutic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Semaglutide: Furosemide may diminish the therapeutic effect of Semaglutide. Semaglutide may increase the serum concentration of Furosemide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sucralfate: May decrease the serum concentration of Furosemide. Sucralfate may impair the absorption of furosemide. Management: Separate orally administered furosemide from sucralfate administration by at least 2 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Furosemide may decrease the protein binding of Thyroid Products. This may lead to a transient increase in free thyroid hormone concentrations and to a later decrease in total thyroid hormone concentrations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobramycin (Oral Inhalation): Loop Diuretics may enhance the nephrotoxic effect of Tobramycin (Oral Inhalation). Loop Diuretics may enhance the ototoxic effect of Tobramycin (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Loop Diuretics may enhance the hypokalemic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaborbactam: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vancomycin: Loop Diuretics may enhance the nephrotoxic effect of Vancomycin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Xipamide: May enhance the adverse/toxic effect of Loop Diuretics. Specifically, the risk of hypovolemia, electrolyte disturbances, and prerenal azotemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zoledronic Acid: Loop Diuretics may enhance the hypocalcemic effect of Zoledronic Acid. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F58530452"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">When diuretics are used for the treatment of heart failure in patients planning to become pregnant, adjust dose prior to conception to minimize risk of placental hypoperfusion (AHA/ACC/HFSA [Heidenreich 2022]).</p></div>
<div class="block pri drugH1Div" id="F174823"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Furosemide crosses the placenta (Beerman 1978; Gonçalves 2020; Riva 1978).</p>
<p style="text-indent:0em;margin-top:2em;">Monitor fetal growth if used during pregnancy (ESC [Regitz-Zagrosek 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of furosemide may be altered. Following administration of a single oral dose of furosemide to patients prior to cesarean delivery, the V<sub>d</sub> and clearance were increased, and the C<sub>max</sub> was lower compared to nonpregnant, healthy individuals (Gonçalves 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Heart failure in pregnancy is associated with adverse maternal and fetal outcomes, including premature birth, infants born small-for-gestational-age, increased risk of maternal and fetal death (Bright 2021). Furosemide may be used for symptom management in pregnant patients with heart failure complicated by pulmonary congestion; closely monitor volume status and adjust dose to minimize risk of placental hypoperfusion (AHA/ACC/HFSA [Heidenreich 2022]; ESC [Regitz-Zagrosek 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Short-term postpartum use of furosemide is being evaluated to reduce the risk of persistent hypertension in patients who had hypertensive disorders of pregnancy (Lopes Perdigao 2021, Veena 2017); additional data needed (Malhamé 2023).</p></div>
<div class="block brc drugH1Div" id="F174824"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Furosemide is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. In general, large doses of loop diuretics have the potential to decrease milk volume and suppress lactation; use should be avoided when possible (WHO 2002). When used for the treatment of heart failure, furosemide may be considered with close neonatal monitoring (AHA/ACC/HFSA [Heidenreich 2022]).</p></div>
<div class="block dic drugH1Div" id="F174825"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May cause potassium loss; potassium supplement or dietary changes may be required.</p></div>
<div class="block mop drugH1Div" id="F174811"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">BP; serum electrolytes; kidney function; fluid intake and output.</p></div>
<div class="block pha drugH1Div" id="F174801"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Primarily inhibits reabsorption of sodium and chloride in the ascending loop of Henle and proximal and distal renal tubules, interfering with the chloride-binding cotransport system, thus causing its natriuretic effect (Rose 1991).</p></div>
<div class="block phk drugH1Div" id="F174819"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Diuresis:</p>
<p style="text-indent:-2em;margin-left:6em;">IV: 5 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">Oral, sublingual (SL): 30 to 60 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Symptomatic improvement with acute pulmonary edema: Within 15 to 20 minutes; occurs prior to diuretic effect.</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral, SL: 1 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">IV:</p>
<p style="text-indent:-2em;margin-left:8em;">Neonates and Infants (mean GA 30.7 weeks [range: 26 to 35 weeks], mean PNA 29 days [range: 10 to 57 days]): 1 to 3 hours (Ross 1978).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults: 0.5 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">SUBQ: 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral, SL: 6 to 8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates and Infants (mean GA 30.7 weeks [range: 26 to 35 weeks], mean PNA 29 days [range: 10 to 57 days]): 6 hours (Ross 1978).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: ~2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 91% to 99%; primarily to albumin.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Minimally hepatic.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral tablet: 47% to 64%; Oral solution: 50%; SUBQ: 99.6%; SL administration of oral tablet: ~60%; results of a small comparative study (n=11) showed bioavailability of SL administration of tablet was ~12% higher than oral administration of tablet (Haegeli 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm neonates:</p>
<p style="text-indent:-2em;margin-left:6em;">GA &lt;28 weeks (PNA &lt;14 days): IV: 15.3 ± 2.3 hours (Okazaki 2022).</p>
<p style="text-indent:-2em;margin-left:6em;">GA 26 to 36 weeks (PNA &lt;21 days): IV: 19.9 ± 3 hours (range: 8.7 to 46 hours) (Peterson 1980).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Oral, IV: Normal kidney function: 0.5 to 2 hours; End-stage kidney disease: 9 hours; SUBQ: 3.2 ± 0.9 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (Oral: 50%, IV: 80%) within 24 hours; feces (as unchanged drug); nonrenal clearance prolonged in kidney impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F174826"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo furosemide | Diomide | Diuresal | Furomex | Fusix | Impugan | Lasix | Lasix faible | Oedemex | Salurin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Dafil | Dafurose | Errolon | Fabofurox | Fada furosemida | Frecuental | Furagrand | Furix | Furosemida | Furosemida denver farma | Furosemida klonal | Furosemida rigo | Furosemida vannier | Furosemida vent 3 | Furotral | Fursemida | Fursemida fabra | Fursemida northia | Furtenk | Kolkin | Lasix | Nuriban | Retep</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Furohexal | Furon | Furosemid-1a pharma gmbh | Furosemid-genericon pharma | Furostad | Furotyrol | Lasix</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cm frusemide | Frusax | Frusehexal | Frusemide | Frusemide an | Frusemide apotex | Frusemide PS | Frusemide rbx | Frusemide Sandoz | Frusemide-bc | Frusemix | Frusemix M | Frusid | Furosemide an | Lasix | Lasix m | Noumed Furosemide | Tw frusemide | Uremide | Urex</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Frunep | Frusemide | Frusin | Frusix | Fusid | Lasix | Renalix | Trofurit | Uratic | Urex</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Docfurose | Furodur | Furosemid ratiopharm | Furosemide eurogenerics | Furosemide sandoz | Furosemide teva generics belgium | Furotop | Lasix</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Furo denk | Lasilix</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Furanthril | Furosemid</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Biosemide | Diflumid | Diuremida | Diuremil | Diurit | Fluxil | Furesin | Furolasil | Furomida | Furosan | Furosantisa | Furosecord | Furosem | Furosemida | Furosemil | Furosemin | Furosetron | Furosix | Furp furosemida | Fursemida | Lasiol | Lasix | Lqfex furosemida | Neosemid | Rosemid | Unifurix | Urasix</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Furo-basan | Furodrix | Furosemid helvepharm | Furosemid UPSA | Furosemid-cophar | Furosemid-trendpharm | Furosemide zentiva | Fursol | Lasix | Oedemex</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Apo furosemide</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Asax | Furosemida | Lasix | Laxur</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Furosemide</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Askast | Diuril | Fluxor | Furomix | Furosemida | Furosemida MK | Hissuflux | Lasix</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo furosemide | Dryptal | Durafurid | Frusemide | Furantral | Furantril | Furesis | Furomex | Furon | Furorese | Furosemid | Furosemid kabi | Furosemid medreg | Furosemid ratiopharm | Furosemid xantis | Furosemidum | Fursemid | Lasix</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Diurapid | Durafurid | Furanthril | Furo 1 A Pharma | Furo abz | Furo biochemie | Furo CT | Furo Lut | Furobeta | Furogamma | Furomed wolff | Furorese | Furosal | Furosemid | Furosemid 1a pharm | Furosemid 3mm | Furosemid al | Furosemid denk | Furosemid Dura | Furosemid Heumann | Furosemid Heumann Heunet | Furosemid ratiopharm | Furosemid Sandoz | Furosemid stada | Fusid | Hydro-rapid-tablinen | Jufurix | Lasix | Oedemase | Sigasalur</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Diural</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Furaced | Furolax | Furosemid | Furosemida | Furosemida lam | Furotil | Lasix</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Asax | Furosemida | Furosemida Genfar | Furosemida MK | Furosemida nifa | Lasix | Odemex</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Frusemide | Frusol | Furesis | Furon | Furosemid | Furosemid-alpharma | Furosemiid ns | Lasix</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Frusemide | Furoretic | Lafurex | Lasix | Odement | Salex</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Acuix | Furosemida | Furosemida alter | Furosemida aphar | Furosemida aurovitas | Furosemida Bexal | Furosemida Cinfa | Furosemida combix | Furosemida ges | Furosemida gesfur | Furosemida Kern Pharma | Furosemida Mabo | Furosemida Mylan | Furosemida Normon | Furosemida pensa | Furosemida ratiopharm | Furosemida Sala | Furosemida Sandoz | Furosemida stada | Furosemida tecnigen | Furosemida teva | Furosemida vir | Seguril</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Furo denk</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Apores | Furesis | Furesis special | Furix | Furomex | Furomin | Furosal | Furotrid | Impugan | Lasix | Lasix special | Vesix | Vesix special</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Furosemide arrow | Furosemide Biogaran | Furosemide dakota | Furosemide eg | Furosemide gnr | Furosemide irex | Furosemide merck | Furosemide ratiopharm | Furosemide rpg | Furosemide sandoz | Furosemide teva | Furosemide Zydus | Furosemix | Lasilix | Lasilix Faible | Lasilix special</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Aluzine | Diuresal | Dryptal | Froop | Frumax | Frusemide | Frusemide almus | Frusemide arrow | Frusemide berk | Frusemide cox | Frusemide dc | Frusemide kent | Frusemide Sandoz | Frusetic | Frusid | Frusol | Furosemide Focus | Furosemide teva | Hydroled | Lasix | Rusyde</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Frusemide | Fudesix | Furanthril | Furosemid | Furosemid germed | Furosemide teva | Hydroflux | Lasix | Salurex | Semid</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo furosemide | Diurex | Frusemide | Frusid | Frutin | Furosemide actavis | Fusid | Lasix | Syn-Furosemide | Urex</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Edemid | Fursemid | Lasix</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Furon | Furosemid | Furosemid al | Furosemid ratiopharm | Huma-semide | Lasix</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Arsiret | Cetasix | Classic | Diurefo | Farsiretic | Farsix | Furosix | Gralixa | Husamid | Impugan | Lasix | Laveric | Naclex | Salurix | Uresix | Yekasix</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Fruside | Frusol | Lasix</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Fusid | Lasix | Miphar</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alfride | Frusemide | Frusenex | Frusix | Furoped | Lasix | Salinex | Urix</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Awafurosem | Furosemide mdi | Lasimex</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Furosemide Angenerico | Furosemide aurobindo | Furosemide l.f.m. | Furosemide merck generics | Lasix</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Diusemide | Lasix</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">A basedock | Accent | Anfuramide kobayashi kako | Anfuramide merck hoei | Beronald | Depix | Diusemide | Foliront | Frusolon | Fulsix | Furfan | Furosedon | Furosemide | Furosemide amel | Furosemide asahikasei | Furosemide isei | Furosemide kayaku | Furosemide merck hoei | Furosemide mita | Furosemide nig | Furosemide s.s. seiyaku | Furosemide shiono | Furosemide showa | Furosemide taiyo | Furosemide takeda teva | Furosemide tobishi | Furosemide towa | Furosemin | Fursein | Fursemait | Fursemide | Furusemadone | Furusemide | Katlex | Kutrix | Lasix | Lowpston | Luseck | Macasirool | Maoread | Moilarorin | Neudiurese | Polysquall | Polysquall a | Profemin | Promedes | Protargen | Radiamin hexal | Radiamin nippon | Radonna | Rasisemide | Rosemide | Synephron | Tabilon a | Urenil | Urex | Urosemide</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Asix | Carefusem | Diuresal | Frusemide | Furo denk | Furomed | Fusid | Lasix | Lefrusid</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dailix | Dairix | Furix | Lasix | Laxed | Rasidine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Furosemide sandoz | Fusix | Lasix</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo Furosemid | Diuresal | Furesix | Furosemid Genericon | Furosetic | Lasix</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Apo Furosemid | Diurapid | Dryptal | Durafurid | Furanthril | Furesis | Furo puren | Furomex | Furon | Furoped | Furosemid | Furosemid bp | Fursemid | Fusid | Lasix</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Docfurose | Furodur | Furorese | Lasix</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Apo Furosemid | Dryptal | Durafurid | Frusemide | Frusix | Furanthril | Furesis | Furo CT | Furomex | Furon | Furosemid | Fursemid | Lasix</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Duresan | Furilan | Lasilix | Lasilix special</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Biomisen | Diufamin | Diurazol | Diurmessel | Diusix | Dromirix | Frudemisan | Furoliz | Furosan | Furosemida | Furosemida hormona | Furosemida iqfa | Furosemida kendrick | Furoter | Klimyn | Lasix | Ordafil | Osemin | Semik</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Dirine | Diuremid | Frucid | Frumid | Frusemide | Frusemide Pharmaniaga | Fruside | Frusix | Furmide | Fusix | Lasix | Rasitol | Trofurit | Usix | Vusimide</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Bakan gizo furosemide | Baraxix | Frucare | Frusatex | Jeklargzis | Lafest | Lasimac | Lasinex | Renix | Shree axis | Tamar &amp; pharez furosemide | Wellcare furosemide</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Furosemide | Furosemide Alpharma | Furosemide CF | Furosemide flx | Furosemide sandoz | Furosemidum | Lasiletten | Lasix</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Diural | Frusol | Furix | Furosemid | Lasix | Lasix liquidum</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo furosemide | Apo-frusemide | Diurin | Frusemide | Frusid | Lasix | Urex Forte</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Diufamin | Frusamil | Furosemida | Lasix | Ragilon</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Dimide | Diurem | Diurema | Diuril | Diuspec | Edemann | Fretic | Frusema | Furix | Furosemide | Fusem | Indiurex | Lasix | Marsemide | Pharmix | Pisamor | Ritemed frusema | Tgp diuretab | Uromid | Veramide</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Aquasin | Asumide | Basix | Diurex | Frusemide | Frusol | Genmide | Lasix | Laxide | Losamide | Odenil | Uremide</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Desal | Furantril | Furosemide medreg | Furosemidum | Lasilix | Lasix</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Furoscix | Furosemide | Lasix</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Entix | Furosemida | Furosemida bluefish | Furosemida Generis | Furosemida Pharmakern | Furosemida Sandoz | Furosemida tolife | Furosemida Zentiva | Lasix | Naqua</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Diuride | Fabofurox | Furosemida | Furosemida heisecke | Hidro max | Lasix | Ragilon | Solax | Urimeg</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Desal | Diusemide | Furomid | Furosemid | Furoxem | Fusix | Lasemid | Lasix | Lasix High Dose | Salurex | Salurin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Furantril | Furomex | Furosemid arena | Furosemid laropharm | Furosemid lph | Furosemid medreg | Furosemid slavia | Furosemid Zentiva | Furosil</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Apo Furosemid | Furon | Furosemid | Furosemid milve | Lasix</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo furosemide | Diusemide | Fusix | Lasix | Salurin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Diural | Furix | Furoscand | Furosemid copyfarm | Furosemid hexal | Furosemid nordic drugs | Furosemid nycomed | Furosemid orifarm | Furosemid recip | Impugan | Lasix</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo furosemide | Dirine | Dryptal | Frumid | Frusemide | Frusix | Furmide | Impugan | Lasix | Rasitol</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Edemid | Furosemida gesfur | Furosemide s.a.l.f. | Fursemid | Lasix</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Furorese | Furosemid | Furosemid slovakofarma | Furosemid xantis | Fursemid</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Aldic | Dema | Difu | Dimasix | Dirine | Diurine | Femide | Fluidsemide | Frusemide | Fruseno | Frusid | Fudirine | Furantral | Furetic | Furide | Furine | Furomide | Furosic | Furoside | Furotic | Fuseride | Fusesian | Hawkmide | Hydril-f | Impugan | Lasemide | Lasix | Lasix high dose | Laton | Losemide | Mediuresix | Mosix | Servisemide</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Ansemid | Furolix special | Lasicare | Lasilix | Lasilix special</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Desal | Furomid | Furotab | Lasix | Lizik | Tts furosemid</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ancoli | Anfuramide | Calitol | Combellin | Diusix | Edemalin | Excresin | F.S | Frusemide | Fuchonropin | Fucochu | Fulsix | Fumide | Furide | Furose | Furosely | Furosin | Furosix | Fursede | Fursemide | Fusemide | Huromide | Kofuzon | Lasemide | Lasix | Liside | Lysix | Nadis | Paiderton | Rasitol | Rosis | Schentese | Seridon | Solmatin | Suopinchon | Tochun | Ureside | Uretropic | Urex | Urian | Uroxin | Yidoli | Yusu</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Frusemid | Furanthril | Furon | Furosemid | Lasix</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Agomide | Asix</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Bios semide | Diusemide | Fischermide | Furoaster | Furosemida Lab. Chile | Furosemide | Furosemide Phs | Lasix</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Biosemida | Fromil | Furolax | Furosemida | Inclens | Lasix | Lifurox | Resimida | Salca</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Agifuros | Furostyl</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Austell Furosemide | Beurises | Defulide | Dino-Retic | Lasix | Merck-furosemide | Micro-furosemide | Mylan furosemide | Puresis | Rolab-furosemide | Uremide</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Amedosix | Diasix | Frusemide | Furo denk | Furosimide | Kamfru</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Aquasin | Diuren | Fruside</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33796993">
<a name="33796993"></a>Abraham S, Rameshkumar R, Chidambaram M, et al. Trial of furosemide to prevent acute kidney injury in critically ill children: a double-blind, randomized, controlled trial. <i>Indian J Pediatr</i>. 2021;88(11):1099-1106. doi:10.1007/s12098-021-03727-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/33796993/pubmed" id="33796993" target="_blank">33796993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20084851">
<a name="20084851"></a>Alim N, Patel JY. Rapid oral desensitization to furosemide. <i>Ann Allergy Asthma Immunol</i>. 2009;103(6):538. doi:10.1016/S1081-1206(10)60274-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/20084851/pubmed" id="20084851" target="_blank">20084851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. Available at https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated September 2023. Accessed October 30, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20107731">
<a name="20107731"></a>Arias-Santiago S, Aneiros-Fernandez J, Aceituno-Madera P, Burkhardt-Perez P, Naranjo Sintes R. Hypertrophic lichenoid eruption due to furosemide. <i>Acta Derm Venereol</i>. 2010;90(1):78-79. doi:10.2340/00015555-0754<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/20107731/pubmed" id="20107731" target="_blank">20107731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9347373">
<a name="9347373"></a>Aufricht C, Votava F, Marx M, et al. Intratracheal furosemide in infants after cardiac surgery: Its effects on lung mechanics and urinary output, and its levels in plasma and tracheal aspirate. <i>Intensive Care Med.</i> 1997;23(9):992-997.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/9347373/pubmed" id="9347373" target="_blank">9347373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27338866">
<a name="27338866"></a>Bauersachs J, Arrigo M, Hilfiker-Kleiner D, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>Eur J Heart Fail</i>. 2016;18(9):1096-1105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/27338866/pubmed" id="27338866" target="_blank">27338866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-699480">
<a name="699480"></a>Beermann B, Groschinsky-Grind M, Fåhraeus L, Lindström B. Placental transfer of furosemide. <i>Clin Pharmacol Ther</i>. 1978;24(5):560-562.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/699480/pubmed" id="699480" target="_blank">699480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: Recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26760044">
<a name="26760044"></a>Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(2):364-389. doi: 10.1210/jc.2015-1710.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/26760044/pubmed" id="26760044" target="_blank">26760044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15303450">
<a name="15303450"></a>Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. <i>Pharmacotherapy</i>. 2004;24(7):856-870.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/15303450/pubmed" id="15303450" target="_blank">15303450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22099505">
<a name="22099505"></a>Brater DC. Update in diuretic therapy: clinical pharmacology. <i>Semin Nephrol</i>. 2011;31(6):483-494. doi: 10.1016/j.semnephrol.2011.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/22099505/pubmed" id="22099505" target="_blank">22099505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6872415">
<a name="6872415"></a>Brater DC, Chennavasin P, Day B, Burdette A, Anderson S. Bumetanide and furosemide. <i>Clin Pharmacol Ther</i>. 1983;34(2):207-213. doi: 10.1038/clpt.1983.154<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/6872415/pubmed" id="6872415" target="_blank">6872415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brater.2020">
<a name="Brater.2020"></a>Brater DC, Ellison DH. Causes and treatment of refractory edema in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 1, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brater.2019a">
<a name="Brater.2019a"></a>Brater DC, Ellison DH. Loop diuretics: Dosing and major side effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 12, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34259013">
<a name="34259013"></a>Bright RA, Lima FV, Avila C, Butler J, Stergiopoulos K. Maternal heart failure. <i>J Am Heart Assoc.</i> 2021;10(14):e021019. doi:10.1161/JAHA.121.021019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/34259013/pubmed" id="34259013" target="_blank">34259013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29409745">
<a name="29409745"></a>Chaabane A, Fadhel NB, Chadli Z, et al. Association of non-immediate drug hypersensitivity with drug exposure: A case control analysis of spontaneous reports from a Tunisian pharmacovigilance database. <i>Eur J Intern Med</i>. 2018;53:40-44. doi:10.1016/j.ejim.2018.01.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/29409745/pubmed" id="29409745" target="_blank">29409745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8074594">
<a name="8074594"></a>Cody RJ, Kubo SH, Pickworth KK. Diuretic treatment for the sodium retention of congestive heart failure. <i>Arch Intern Med</i>. 1994;154(17):1905-1914.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/8074594/pubmed" id="8074594" target="_blank">8074594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Colucci.2019">
<a name="Colucci.2019"></a>Colucci WS. Treatment of acute decompensated heart failure: Specific therapies. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6650766">
<a name="6650766"></a>Copeland JG, Campbell DW, Plachetka JR, et al. Diuresis with continuous infusion of furosemide after cardiac surgery. <i>Am J Surg.</i> 1983;146(6):796-769.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/6650766/pubmed" id="6650766" target="_blank">6650766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4842808">
<a name="4842808"></a>Cutler RE, Forrey AW, Christopher TG, Kimpel BM. Pharmacokinetics of furosemide in normal subjects and functionally anephric patients. <i>Clin Pharmacol Ther</i>. 1974;15(6):588-596. doi:10.1002/cpt1974156588<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/4842808/pubmed" id="4842808" target="_blank">4842808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10369265">
<a name="10369265"></a>Delpire E, Lu J, England R, Dull C, Thorne T. Deafness and imbalance associated with inactivation of the secretory Na-K-2Cl co-transporter. <i>Nat Genet</i>. 1999;22(2):192-195. doi:10.1038/9713<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/10369265/pubmed" id="10369265" target="_blank">10369265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19142668">
<a name="19142668"></a>Dharmaraj R, Hari P, Bagga A. Randomized cross-over trial comparing albumin and frusemide infusions in nephrotic syndrome. <i>Pediatr Nephrol</i>. 2009;24(4):775-782. doi:10.1007/s00467-008-1062-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/19142668/pubmed" id="19142668" target="_blank">19142668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29937824">
<a name="29937824"></a>Ding D, Liu H, Qi W, et al. Ototoxic effects and mechanisms of loop diuretics. <i>J Otol</i>. 2016;11(4):145-156. doi:10.1016/j.joto.2016.10.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/29937824/pubmed" id="29937824" target="_blank">29937824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14670291">
<a name="14670291"></a>Domínguez-Ortega J, Martínez-Alonso JC, Domínguez-Ortega C, Fuentes MJ, Frades A, Fernández-Colino T. Anaphylaxis to oral furosemide. <i>Allergol Immunopathol (Madr)</i>. 2003;31(6):345-347. doi:10.1016/s0301-0546(03)79210-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/14670291/pubmed" id="14670291" target="_blank">14670291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8800113">
<a name="8800113"></a>Dormans TP, van Meyel JJ, Gerlag PG, Tan Y, Russel FG, Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. <i>J Am Coll Cardiol</i>. 1996;28(2):376-382. doi:10.1016/0735-1097(96)00161-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/8800113/pubmed" id="8800113" target="_blank">8800113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19957078">
<a name="19957078"></a>Ebdrup L, Pedersen CM, Andersen MH, Storgaard M. Prolonged hyperthermia from furosemide infusion--a case report. <i>Eur J Clin Pharmacol</i>. 2010;66(2):215-216. doi:10.1007/s00228-009-0761-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/19957078/pubmed" id="19957078" target="_blank">19957078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Erkan.1">
<a name="Erkan.1"></a>Erkan E. Nephrotic syndrome. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020:chap. 545.1.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21366472">
<a name="21366472"></a>Felker GM, Lee KL, Bull DA, et al; NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. <i>N Engl J Med</i>. 2011;364(9):797-805. doi: 10.1056/NEJMoa1005419<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/21366472/pubmed" id="21366472" target="_blank">21366472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22676934">
<a name="22676934"></a>Felker GM, Mentz RJ. Diuretics and ultrafiltration in acute decompensated heart failure. <i>J Am Coll Cardiol</i>. 2012;59(24):2145-2153. doi: 10.1016/j.jacc.2011.10.910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/22676934/pubmed" id="22676934" target="_blank">22676934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21242810">
<a name="21242810"></a>Flynn JT. Management of hypertension in the young: role of antihypertensive medications. <i>J Cardiovasc Pharmacol</i>. 2011;58(2):111-120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/21242810/pubmed" id="21242810" target="_blank">21242810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fuhrman.2017">
<a name="Fuhrman.2017"></a>Fuhrman B, Zimmerman J, eds.<i> Pediatric Critical Care</i>. 5th ed. Elsevier Health; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi:10.1210/jc.2015-4061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-csPharmaceuticals.1">
<a name="csPharmaceuticals.1"></a>Furoscix (furosemide) [prescribing information]. Burlington, MA: csPharmaceuticals Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FurosemideInj.2018.05">
<a name="FurosemideInj.2018.05"></a>Furosemide injection (USP) [prescribing information]. Lake Zurich, IL: Fresenius Kabi; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.1">
<a name="Hospira.1"></a>Furosemide injection [prescribing information]. Lake Forest, IL: Hospira Inc; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Furosemideinj.2.2023">
<a name="Furosemideinj.2.2023"></a>Furosemide injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Teligent.1">
<a name="Teligent.1"></a>Furosemide injection (USP) [product monograph]. Mississauga, Ontario, Canada: Hikma Canada Limited; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FurosemideTab.2016.01">
<a name="FurosemideTab.2016.01"></a>Furosemide tablet, solution [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals Corp.; January 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FurosemideTab.2017.03">
<a name="FurosemideTab.2017.03"></a>Furosemide tablets [prescribing information]. Cranbury, NJ: Solco Healthcare US, LLC; March 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-496112">
<a name="496112"></a>Gallagher KL, Jones JK. Furosemide-induced ototoxicity. <i>Ann Intern Med</i>. 1979;91(5):744-745. doi:10.7326/0003-4819-91-5-744<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/496112/pubmed" id="496112" target="_blank">496112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32562572">
<a name="32562572"></a>Gonçalves PVB, Moreira FL, Benzi JRL, Duarte G, Lanchote VL. A pilot study of the maternal-fetal pharmacokinetics of furosemide in plasma, urine, and amniotic fluid of hypertensive parturient women under cesarean section. <i>J Clin Pharmacol.</i> 2020;60(12):1655-1661. doi:10.1002/jcph.1681<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/32562572/pubmed" id="32562572" target="_blank">32562572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10653441">
<a name="10653441"></a>Greenberg A. Diuretic complications. <i>Am J Med Sci</i>. 2000;319(1):10-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/10653441/pubmed" id="10653441" target="_blank">10653441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17875188">
<a name="17875188"></a>Haegeli L, Brunner-La Rocca HP, Wenk M, et al. Sublingual administration of furosemide: New application of an old drug. <i>Br J Clin Pharmacol.</i> 2007;64(6):804-809.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/17875188/pubmed" id="17875188" target="_blank">17875188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3668117">
<a name="3668117"></a>Hansbrough JR, Wedner HJ, Chaplin DD. Anaphylaxis to intravenous furosemide. <i>J Allergy Clin Immunol</i>. 1987;80(4):538-541. doi:10.1016/0091-6749(87)90004-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/3668117/pubmed" id="3668117" target="_blank">3668117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18048421">
<a name="18048421"></a>Hayashi SY, Seeberger A, Lind B, et al. Acute effects of low and high intravenous doses of furosemide on myocardial function in anuric haemodialysis patients: a tissue Doppler study. <i>Nephrol Dial Transplant</i>. 2008;23(4):1355-1361. doi:10.1093/ndt/gfm805<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/18048421/pubmed" id="18048421" target="_blank">18048421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-320943">
<a name="320943"></a>Hendricks WM, Ader RS. Furosemide-induced cutaneous necrotizing vasculitis. <i>Arch Dermatol</i>. 1977;113(3):375.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/320943/pubmed" id="320943" target="_blank">320943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20085566">
<a name="20085566"></a>Ho KM, Power BM. Benefits and risks of furosemide in acute kidney injury. <i>Anaesthesia</i>. 2010;65(3):283-293. doi:10.1111/j.1365-2044.2009.06228.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/20085566/pubmed" id="20085566" target="_blank">20085566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31526538">
<a name="31526538"></a>Hollenberg SM, Warner Stevenson L, Ahmad T, et al. 2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol</i>. 2019;74(15):1966-2011. doi:10.1016/j.jacc.2019.08.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/31526538/pubmed" id="31526538" target="_blank">31526538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9165341">
<a name="9165341"></a>Ikeda K, Oshima T, Hidaka H, Takasaka T. Molecular and clinical implications of loop diuretic ototoxicity. <i>Hear Res</i>. 1997;107(1-2):1-8. doi:10.1016/s0378-5955(97)00009-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/9165341/pubmed" id="9165341" target="_blank">9165341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25138826">
<a name="25138826"></a>Inder WJ, Meyer C, Hunt PJ. Management of hypertension and heart failure in patients with Addison's disease. <i>Clin Endocrinol (Oxf)</i>. 2015;82(6):789-792. doi:10.1111/cen.12592<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/25138826/pubmed" id="25138826" target="_blank">25138826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jackson.1">
<a name="Jackson.1"></a>Jackson EK. Drugs affecting renal excretory function. In: Brunton LL, Hilal-Dandan R, Knollmann BC, eds. <i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i>. 13th ed. McGraw Hill; 2018: chap. 25.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29440628">
<a name="29440628"></a>James J, Sammour YM, Virata AR, Nordin TA, Dumic I. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome secondary to furosemide: Case report and review of literature. <i>Am J Case Rep</i>. 2018;19:163-170. doi:10.12659/ajcr.907464<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/29440628/pubmed" id="29440628" target="_blank">29440628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3701771">
<a name="3701771"></a>Jennings M, Shortland JR, Maddocks JL. Interstitial nephritis associated with frusemide. <i>J R Soc Med</i>. 1986;79(4):239-240. doi:10.1177/014107688607900416<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/3701771/pubmed" id="3701771" target="_blank">3701771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15644481">
<a name="15644481"></a>Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? [published correction appears in Ann <i>Pharmacother</i>. 2005;39(7-8):1373]. <i>Ann Pharmacother</i>. 2005;39(2):290-301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/15644481/pubmed" id="15644481" target="_blank">15644481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16105640">
<a name="16105640"></a>Juang P, Page RL 2nd, Zolty R. A successful rapid desensitization protocol in a loop diuretic allergic patient. <i>J Card Fail</i>. 2005;11(6):481. doi:10.1016/j.cardfail.2005.03.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/16105640/pubmed" id="16105640" target="_blank">16105640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16352777">
<a name="16352777"></a>Juang P, Page RL 2nd, Zolty R. Probable loop diuretic-induced pancreatitis in a sulfonamide-allergic patient. <i>Ann Pharmacother</i>. 2006;40(1):128-134. doi:10.1345/aph.1G314<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/16352777/pubmed" id="16352777" target="_blank">16352777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7120755">
<a name="7120755"></a>Kaojarern S, Day B, Brater DC. The time course of delivery of furosemide into urine: an independent determinant of overall response. <i>Kidney Int</i>. 1982;22(1):69-74. doi:10.1038/ki.1982.134<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/7120755/pubmed" id="7120755" target="_blank">7120755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31495421">
<a name="31495421"></a>Khan DA, Knowles SR, Shear NH. Sulfonamide hypersensitivity: Fact and fiction. <i>J Allergy Clin Immunol Pract</i>. 2019;7(7):2116-2123. doi:10.1016/j.jaip.2019.05.034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/31495421/pubmed" id="31495421" target="_blank">31495421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lasix.2018.08">
<a name="Lasix.2018.08"></a>Lasix (furosemide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US; August 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lasix.2018.02">
<a name="Lasix.2018.02"></a>Lasix Oral Solution (furosemide) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LasixSpecial.2018.02">
<a name="LasixSpecial.2018.02"></a>Lasix Special (furosemide) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31657712">
<a name="31657712"></a>Leclerc S, Laurin LP, Lafrance JP, et al. Pharmacodynamics of 250 mg and 500 mg oral furosemide in peritoneal dialysis. <i>Int J</i>
<i>Clin Pharmacol Ther</i>. 2019;57(12):603-606. doi:10.5414/CP203594<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/31657712/pubmed" id="31657712" target="_blank">31657712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20234144">
<a name="20234144"></a>Lee BS, Byun SY, Chung ML, et al. Effect of furosemide on ductal closure and renal function in indomethacin-treated preterm infants during the early neonatal period. <i>Neonatology</i>. 2010;98(2):191-199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/20234144/pubmed" id="20234144" target="_blank">20234144</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16774111">
<a name="16774111"></a>Lee JJ, Downham TF 2nd. Furosemide-induced bullous pemphigoid: case report and review of literature. <i>J Drugs Dermatol</i>. 2006;5(6):562-564<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/16774111/pubmed" id="16774111" target="_blank">16774111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22641414">
<a name="22641414"></a>Levi TM, Rocha MS, Almeida DN, et al. Furosemide is associated with acute kidney injury in critically ill patients. <i>Braz J Med Biol Res</i>. 2012;45(9):827-833. doi:10.1590/s0100-879x2012007500093<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/22641414/pubmed" id="22641414" target="_blank">22641414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33824870">
<a name="33824870"></a>Liu C, Yan S, Wang Y, et al. Drug-induced hospital-acquired acute kidney injury in China: a multicenter cross-sectional survey. <i>Kidney Dis (Basel)</i>. 2021;7(2):143-155. doi:10.1159/000510455<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/33824870/pubmed" id="33824870" target="_blank">33824870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33550824">
<a name="33550824"></a>Lopes Perdigao J, Lewey J, Hirshberg A, et al. Furosemide for accelerated recovery of blood pressure postpartum in women with a hypertensive disorder of pregnancy: a randomized controlled trial. <i>Hypertension</i>. 2021;77(5):1517-1524. doi:10.1161/HYPERTENSIONAHA.120.16133<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/33550824/pubmed" id="33550824" target="_blank">33550824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9354540">
<a name="9354540"></a>Luciani GB, Nichani S, Chang AC, et al. Continuous Versus Intermittent Furosemide Infusion in Critically Ill Infants After Open Heart Operations. <i>Ann Thorac Surg</i>. 1997;64(4):1133-1139.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/9354540/pubmed" id="9354540" target="_blank">9354540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29167185">
<a name="29167185"></a>Ma BJ. Hyperacute leucopenia associated with furosemide. <i>BMJ Case Rep</i>. 2017;2017:bcr2016218776. doi:10.1136/bcr-2016-218776<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/29167185/pubmed" id="29167185" target="_blank">29167185</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15946061">
<a name="15946061"></a>Maddox NI, Futral D, Boudreau FT. Serologic investigation of fatal hemolytic anemia associated with a multiple drug history and Rh-like autoantibody. <i>Immunohematology</i>. 1992;8(3):70-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/15946061/pubmed" id="15946061" target="_blank">15946061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26951244">
<a name="26951244"></a>Malha L, Mann SJ. Loop diuretics in the treatment of hypertension. <i>Curr Hypertens Rep</i>. 2016;18(4):27. doi:10.1007/s11906-016-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/26951244/pubmed" id="26951244" target="_blank">26951244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36453652">
<a name="36453652"></a>Malhamé I, Dong S, Syeda A, et al. The use of loop diuretics in the context of hypertensive disorders of pregnancy: a systematic review and meta-analysis. <i>J Hypertens.</i> 2023;41(1):17-26. doi:10.1097/HJH.0000000000003310<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/36453652/pubmed" id="36453652" target="_blank">36453652</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8641327">
<a name="8641327"></a>Martin U, Winney RJ, Prescott LF. Furosemide disposition in patients on CAPD. <i>Eur J Clin Pharmacol</i>. 1995;48(5):385-390. doi:10.1007/BF00194955<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/8641327/pubmed" id="8641327" target="_blank">8641327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32232733">
<a name="32232733"></a>Meena J, Bagga A. Current perspectives in management of edema in nephrotic syndrome. <i>Indian J Pediatr</i>. 2020;87(8):633-640. doi:10.1007/s12098-020-03252-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/32232733/pubmed" id="32232733" target="_blank">32232733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24897942">
<a name="24897942"></a>Miller JL, Thomas AN, Johnson PN. Use of continuous-infusion loop diuretics in critically ill children. <i>Pharmacotherapy</i>. 2014;34(8):858-867. doi:10.1002/phar.1443<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/24897942/pubmed" id="24897942" target="_blank">24897942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3351693">
<a name="3351693"></a>Mirochnick MH, Miceli JJ, Kramer PA, et al. Furosemide pharmacokinetics in very low birth weight infants. <i>J Pediatr</i>. 1988;112(4):653-657.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/3351693/pubmed" id="3351693" target="_blank">3351693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12020173">
<a name="12020173"></a>Moore DE. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. <i>Drug Saf</i>. 2002;25(5):345-372. doi:10.2165/00002018-200225050-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/12020173/pubmed" id="12020173" target="_blank">12020173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9017769">
<a name="9017769"></a>Murray MD, Haag KM, Black PK, Hall SD, Brater DC. Variable furosemide absorption and poor predictability of response in elderly patients. <i>Pharmacotherapy</i>. 1997;17(1):98-106.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/9017769/pubmed" id="9017769" target="_blank">9017769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15286277">
<a name="15286277"></a>National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. <i>Pediatrics.</i> 2004;114(2)(suppl):555-576.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/15286277/pubmed" id="15286277" target="_blank">15286277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>National Clinical Guideline Centre (NICE). Drug allergy. Diagnosis and management of drug allergy in adults, children and young people. September 2014: Clinical guideline 183.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11093686">
<a name="11093686"></a>Noce R, Paredes BE, Pichler WJ, Krähenbühl S. Acute generalized exanthematic pustulosis (AGEP) in a patient treated with furosemide. <i>Am J Med Sci</i>. 2000;320(5):331-333. doi:10.1097/00000441-200011000-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/11093686/pubmed" id="11093686" target="_blank">11093686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23625769">
<a name="23625769"></a>Ochoa PS, Fisher T. A 7-year case of furosemide-induced immune thrombocytopenia. <i>Pharmacotherapy</i>. 2013;33(7):e162-e165. doi:10.1002/phar.1279<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/23625769/pubmed" id="23625769" target="_blank">23625769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26240596">
<a name="26240596"></a>Oh SW, Han SY. Loop diuretics in clinical practice. <i>Electrolyte Blood Press</i>. 2015;13(1):17-21. doi:10.5049/EBP.2015.13.1.17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/26240596/pubmed" id="26240596" target="_blank">26240596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33848384">
<a name="33848384"></a>Okazaki K, Fukuoka N, Kuboi T, et al. Furosemide clearance in very preterm neonates early in life: a pilot study using scavenged samples. <i>Pediatr Int</i>. 2022;64(1):e14735. doi:10.1111/ped.14735<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/33848384/pubmed" id="33848384" target="_blank">33848384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22099511">
<a name="22099511"></a>Palmer BF. Metabolic complications associated with use of diuretics. <i>Semin Nephrol</i>. 2011;31(6):542-552. doi:10.1016/j.semnephrol.2011.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/22099511/pubmed" id="22099511" target="_blank">22099511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7381633">
<a name="7381633"></a>Peterson RG, Simmons MA, Rumack BH, Levine RL, Brooks JG. Pharmacology of furosemide in the premature newborn infant. <i>J Pediatr</i>. 1980;97(1):139-143. doi:10.1016/s0022-3476(80)80154-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/7381633/pubmed" id="7381633" target="_blank">7381633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-622611">
<a name="622611"></a>Rifkin SI, de Quesada AM, Pickering MJ, Shires DL Jr. Deafness associated with oral furosemide. <i>South Med J</i>. 1978;71(1):86-88. doi:10.1097/00007611-197801000-00029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/622611/pubmed" id="622611" target="_blank">622611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-729629">
<a name="729629"></a>Riva E, Farina P, Tognoni G, Bottino S, Orrico C, Pardi G. Pharmacokinetics of furosemide in gestosis of pregnancy. <i>Eur J Clin Pharmacol</i>. 1978;14(5):361-366.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/729629/pubmed" id="729629" target="_blank">729629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosanno.1">
<a name="Rosanno.1"></a>Rosanno JW. Heart failure. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020:chap. 469.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2002648">
<a name="2002648"></a>Rose BD. Diuretics. <i>Kidney Int</i>. 1991;39(2):336-352.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/2002648/pubmed" id="2002648" target="_blank">2002648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22591">
<a name="22591"></a>Ross BS, Pollak A, Oh W. The pharmacologic effects of furosemide therapy in the low-birth-weight infant. <i>J Pediatr</i>. 1978;92(1):149-152. doi:10.1016/s0022-3476(78)80098-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/22591/pubmed" id="22591" target="_blank">22591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Runyon.2020">
<a name="Runyon.2020"></a>Runyon BA. Ascites in adults with cirrhosis: Initial therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23463403">
<a name="23463403"></a>Runyon BA; American Association for the Study of Liver Diseases. Introduction to the revised American Association for the Study of Liver Diseases practice guideline management of adult patients with ascites due to cirrhosis 2012. <i>Hepatology</i>. 2013;57(4):1651-1653. doi:10.1002/hep.26359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/23463403/pubmed" id="23463403" target="_blank">23463403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7042998">
<a name="7042998"></a>Rybak LP. Pathophysiology of furosemide ototoxicity. <i>J Otolaryngol</i>. 1982;11(2):127-133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/7042998/pubmed" id="7042998" target="_blank">7042998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8233492">
<a name="8233492"></a>Rybak LP. Ototoxicity of loop diuretics. <i>Otolaryngol Clin North Am</i>. 1993;26(5):829-844.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/8233492/pubmed" id="8233492" target="_blank">8233492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12386640">
<a name="12386640"></a>Schoemaker RC, van der Vorst MMJ, van Heel IR, Cohen AF, Burggraaf J; Pediatric Pharmacology Network. Development of an optimal furosemide infusion strategy in infants with modeling and simulation. <i>Clin Pharmacol Ther</i>. 2002;72(4):383-390.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/12386640/pubmed" id="12386640" target="_blank">12386640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21896142">
<a name="21896142"></a>Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. <i>J Clin Hypertens (Greenwich)</i>. 2011;13(9):639-643. doi:10.1111/j.1751-7176.2011.00512.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/21896142/pubmed" id="21896142" target="_blank">21896142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1729038">
<a name="1729038"></a>Singh NC, Kissoon N, al Mofada S, Bennett M, Bohn DJ. Comparison of continuous versus intermittent furosemide administration in postoperative pediatric cardiac patients. <i>Crit Care Med</i>. 1992;20(1):17-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/1729038/pubmed" id="1729038" target="_blank">1729038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23756362">
<a name="23756362"></a>Skeith L, Yamashita C, Mehta S, Farquhar D, Kim RB. Sildenafil and furosemide associated ototoxicity: consideration of drug-drug interactions, synergy, and broader clinical relevance. <i>J Popul Ther Clin Pharmacol</i>. 2013;20(2):e128-e131.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/23756362/pubmed" id="23756362" target="_blank">23756362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27388387">
<a name="27388387"></a>Sladden D, Mizzi S, Casha AR, Manché A. Furosemide-induced eruption of haemorrhagic bullae on the fingers. <i>Br J Hosp Med (Lond)</i>. 2016;77(7):428-429. doi:10.12968/hmed.2016.77.7.428<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/27388387/pubmed" id="27388387" target="_blank">27388387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15242722">
<a name="15242722"></a>Slatore CG, Tilles SA. Sulfonamide hypersensitivity. <i>Immunol Allergy Clin North Am</i>. 2004;24(3):477-490.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/15242722/pubmed" id="15242722" target="_blank">15242722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Steinhorn.1">
<a name="Steinhorn.1"></a>Steinhorn RH, Davis JM. Bronchopulmonary dysplasia. In: Boardman J, Groves A, Ramasethu J, eds. <i>Avery &amp; MacDonald's Neonatology</i>. 8th ed. LWW; 2021:chap. 29.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sterns.2019">
<a name="Sterns.2019"></a>Sterns RH. General principles of the treatment of edema in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-TevaFurosemide.2020.03">
<a name="TevaFurosemide.2020.03"></a>Teva-Furosemide tablets [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29752171">
<a name="29752171"></a>Thompson EJ, Greenberg RG, Kumar K, et al. Association between furosemide exposure and patent ductus arteriosus in hospitalized infants of very low birth weight. <i>J Pediatr</i>. 2018;199:231-236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/29752171/pubmed" id="29752171" target="_blank">29752171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15373844">
<a name="15373844"></a>Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. <i>Contact Dermatitis</i>. 2004;51(2):57-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/15373844/pubmed" id="15373844" target="_blank">15373844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16898855">
<a name="16898855"></a>van der Vorst MM, Kist JE, van der Heijden AJ, Burggraaf J. Diuretics in pediatrics : current knowledge and future prospects. <i>Paediatr Drugs</i>. 2006;8(4):245-264.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/16898855/pubmed" id="16898855" target="_blank">16898855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11398698">
<a name="11398698"></a>van der Vorst MM, Ruys-Dudok van Heel I, Kist-van Holthe JE, et al. Continuous intravenous furosemide in haemodynamically unstable children after cardiac surgery. <i>Intensive Care Med</i>. 2001;27(4):711-715.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/11398698/pubmed" id="11398698" target="_blank">11398698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7781259">
<a name="7781259"></a>Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. <i>Clin Pharmacol Ther</i>. 1995;57(6):601-609. doi:10.1016/0009-9236(95)90222-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/7781259/pubmed" id="7781259" target="_blank">7781259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27835048">
<a name="27835048"></a>Veena P, Perivela L, Raghavan SS. Furosemide in postpartum management of severe preeclampsia: a randomized controlled trial. <i>Hypertens Pregnancy</i>. 2017;36(1):84-89. doi:10.1080/10641955.2016.1239735<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/27835048/pubmed" id="27835048" target="_blank">27835048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Velat.2020">
<a name="Velat.2020"></a>Velat I, Busic Z, Paic MJ, Culic V. Furosemide and spironolactone doses and hyponatremia in patients with heart failure. <i>BMC Pharmacol Toxicol</i>. 2020;21:57. https://doi.org/10.1186/s40360-020-00431-4</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VON.1">
<a name="VON.1"></a>Vermont Oxford Network (VON). Neonatal drug concentrations. https://public.vtoxford.org/wp-content/uploads/2022/11/Neonatal-Drug-Concentrations-Updated-November-2022.pdf. Updated November 2022. Accessed August 15, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24341872">
<a name="24341872"></a>Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26. doi:10.1111/jch.12237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/24341872/pubmed" id="24341872" target="_blank">24341872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2184406">
<a name="2184406"></a>Wells TG. The pharmacology and therapeutics of diuretics in the pediatric patient. <i>Pediatr Clin North Am</i>. 1990;37(2):463-504.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/2184406/pubmed" id="2184406" target="_blank">2184406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published online ahead of print on November 13, 2017.]. <i>Hypertension</i>. 2017. doi:10.1161/HYP.0000000000000065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2002">
<a name="WHO.2002"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21507837">
<a name="21507837"></a>Wright AA, Vesta KS, Stark JE, Smith WJ. Stevens-Johnson syndrome associated with furosemide: a case report. <i>J Pharm Pract</i>. 2010;23(4):367-370. doi:10.1177/0897190010362260<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/21507837/pubmed" id="21507837" target="_blank">21507837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24940940">
<a name="24940940"></a>Wu X, Zhang W, Ren H, Chen X, Xie J, Chen N. Diuretics associated acute kidney injury: clinical and pathological analysis. <i>Ren Fail</i>. 2014;36(7):1051-1015. doi:10.3109/0886022X.2014.917560<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/24940940/pubmed" id="24940940" target="_blank">24940940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23943179">
<a name="23943179"></a>Wulf NR, Matuszewski KA. Sulfonamide cross-reactivity: is there evidence to support broad cross-allergenicity? <i>Am J Health Syst Pharm</i>. 2013;70(17):1483-1494. doi:10.2146/ajhp120291<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/23943179/pubmed" id="23943179" target="_blank">23943179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20152742">
<a name="20152742"></a>Ziegler O, Sirveaux MA, Brunaud L, Reibel N, Quilliot D. Medical follow up after bariatric surgery: nutritional and drug issues. General recommendations for the prevention and treatment of nutritional deficiencies. <i>Diabetes Metab</i>. 2009;35(6, pt 2):544-557. doi:10.1016/S1262-3636(09)73464-0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/20152742/pubmed" id="20152742" target="_blank">20152742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7377783">
<a name="7377783"></a>Zugerman C, La Voo EJ. Erythema multiforme caused by oral furosemide. <i>Arch Dermatol</i>. 1980;116(5):518-519.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/furosemide-drug-information/abstract-text/7377783/pubmed" id="7377783" target="_blank">7377783</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8482 Version 692.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
